Platelet-released serotonin drives lung pathology in a mouse model of age-associated disease severity after SARS-CoV-2 infection, and pharmacologic or genetic disruption of serotonin uptake or signaling protected against respiratory distress independently of viral replication and immune responses.
Key Findings
Results
Middle-aged mice showed enhanced platelet serotonin release upon activation compared to younger mice, associated with increased morbidity and respiratory dysfunction after SARS-CoV-2 infection.
A mouse model of age-associated disease severity was used to study SARS-CoV-2 pathology
Middle-aged mice exhibited greater morbidity after SARS-CoV-2 infection compared to younger counterparts
Enhanced serotonin release was documented upon platelet activation in middle-aged mice
Respiratory dysfunction was a primary outcome measure distinguishing age groups
Results
Aged human healthy donors also showed enhanced platelet serotonin release upon activation, paralleling the findings in middle-aged mice.
Human samples from aged healthy donors were analyzed alongside the mouse model
Platelet serotonin release upon activation was enhanced in aged human donors
This finding supports the translational relevance of the mouse model to human aging
The parallel between mouse and human data suggests a conserved age-related mechanism
Results
Activated platelets aggregated and promoted fibrin deposition in the lung microvasculature in the context of SARS-CoV-2 infection and aging.
Platelet aggregation was observed specifically in the lung microvasculature
Fibrin deposition in lung microvasculature was documented as a key pathological feature
This procoagulant activity was associated with increased disease severity in middle-aged mice
The findings implicate serotonin-driven platelet procoagulant activity as a key contributor to age-related lung dysfunction
Results
Pharmacologic disruption of serotonin uptake attenuated platelet activation and protected against respiratory distress independently of viral replication and immune responses.
Pharmacologic inhibition of serotonin uptake was tested as a therapeutic intervention
Protection against respiratory distress was achieved without affecting viral replication
Immune responses were also unaffected by the serotonin uptake inhibition
This suggests serotonin-mediated pathology operates through a mechanism distinct from antiviral immunity
Results
Genetic disruption of serotonin uptake similarly attenuated platelet activation and protected against respiratory distress independently of viral replication and immune responses.
Genetic approaches targeting serotonin uptake were used in addition to pharmacologic methods
Protection from respiratory distress was confirmed using genetic disruption, corroborating the pharmacologic findings
Viral replication and immune responses remained unaltered in genetically modified animals
The convergence of genetic and pharmacologic data strengthens the causal role of serotonin uptake in platelet-driven pathology
Results
Blockade of serotonin-dependent signaling attenuated platelet activation and protected against respiratory distress independently of viral replication and immune responses.
Serotonin receptor/signaling blockade was tested as a third therapeutic strategy
This approach also attenuated platelet activation in the context of SARS-CoV-2 infection
Protection was independent of effects on viral replication or immune responses
Three independent intervention strategies (pharmacologic uptake inhibition, genetic uptake disruption, signaling blockade) all converged on the same protective outcome
Results
Inhibition of fibrin formation reduced disease severity, implicating serotonin-driven platelet procoagulant activity as a key contributor to age-related lung dysfunction.
Fibrin formation inhibition was tested as a downstream intervention in the serotonin-platelet pathway
Reduction of disease severity was observed upon fibrin formation inhibition
This result mechanistically links serotonin-driven platelet procoagulant activity to lung pathology
The finding positions fibrin deposition as a critical downstream effector of serotonin-mediated disease
Conclusions
Serotonin-mediated platelet procoagulant activity is identified as a major contributor to respiratory insufficiency during SARS-CoV-2 infection and a potential therapeutic target, particularly in the elderly.
The study concludes that serotonin-mediated platelet procoagulant activity is a 'major contributor to respiratory insufficiency during SARS-CoV-2 infection'
The mechanism is described as a 'potential therapeutic target for preserving pulmonary function, particularly in the elderly'
Multiple existing drug classes (serotonin uptake inhibitors, serotonin receptor blockers, anticoagulants) could potentially be repurposed based on these findings
The therapeutic effect was demonstrated to be independent of antiviral or immunological mechanisms
What This Means
This research suggests that a molecule called serotonin, which is stored in blood platelets (tiny blood cells involved in clotting), plays a central role in why older people tend to get much sicker from COVID-19 than younger people. The researchers found that as mice age into middle age, their platelets release more serotonin when activated, and this excess serotonin drives the platelets to clump together and promote the formation of fibrin (a clotting protein) in the tiny blood vessels of the lungs. This clotting activity physically disrupts lung function and causes breathing problems. Importantly, the same pattern of enhanced platelet serotonin release with age was also found in blood samples from older healthy human donors, suggesting the mouse findings are relevant to human disease.
The study tested several ways to interfere with this serotonin-platelet pathway: blocking serotonin from being taken up into platelets (using drugs or genetic modification), blocking serotonin's downstream signaling, and directly preventing fibrin from forming. All of these approaches reduced lung damage and respiratory distress in infected mice. Crucially, none of these interventions affected how well the immune system fought the virus or how much virus replicated in the body — meaning the protection came purely from reducing the harmful clotting activity, not from any antiviral effect.
This research suggests that the severe breathing problems seen in elderly COVID-19 patients may be substantially driven by an age-related change in platelet behavior rather than just by differences in immune responses or viral load. It raises the possibility that existing drugs that affect serotonin signaling or blood clotting — some of which are already widely used — could be repurposed to protect lung function in older COVID-19 patients. More broadly, these findings point to platelet serotonin activity as a potential target for reducing COVID-19 severity in aging populations.